Supporting Information

Transferrin receptor-targeted PEG-PLA Polymeric Micelles for Chemotherapy against Glioblastoma multiforme

Ping Sun^{1,2}, Ph.D., Yue Xiao¹, Ph.D., Qianqian Di¹, Ph.D., Wenjing Ma¹, M.S., Xingyu Ma¹, M.S., Qingqing Wang³, Ph.D., Weilin Chen¹, Ph.D.

¹Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Immunology, Shenzhen University School of Medicine, Shenzhen, 518060 China

²Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Health Science Center, Shenzhen 518060, China

³Institute of Immunology, Zhejiang University of Mediine School, Hangzhou, Zhejiang, 310058, China

E-mail: <u>cwl@szu.edu.cn</u>. (W.Chen)




Figure S1:The synthetic route of TfR-T12-PEG-PLA copolymer, EDC/NHS was used to activator for reaction 24h.

Abbreviations: EDC, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide-2-

hydrochloride; NHS, N-Hydroxysuccinimide.




Figure S2: ¹H-NMR spectroscopy of TfR-T12 peptide (A) and PEG-PLA (B). Abbreviations:TfR-T12, Transferrin Receptor-T12 peptide; PEG-PLA, Poly(ethylene glycol)-b-poly(L-lactide-co-glycolide).




Figure S3: Toxicity evaluation of TfR-T12-PEG-PLA copolymer within 0-100mg/ml concentration in A172, U87MG and U118 cells, the cell viability was above 90% in every group.

Abbreviations: TfR-T12, Transferrin Receptor-T12 peptide.




Figure S4: The zeta potential distribution of PEG-PMs (A)and TfR-T12-PMs (B).Abbreviations:PEG-PLA/PTXPolymerMicelles;TfR-T12-PMs,TfR-T12-PEG-PLA/ PTX Polymer Micelles.




Figure S5: Schematic of the *in vitro* BBB/BBTB model, which is formed by HUVECs /U87MG cells co-culture over the transwell insert for 3days.

Abbreviations: BBB, Blood-Brain Barrier; BBTB, Blood-Brain Tumor Barrier




Figure S6: The hoechst staining observation of U87MG cells treated with different PTX formulations after HUVEC/U87MG co-culture, PBS was as control group, and the red arrow represents U87MG apoptosis.

Abbreviations: PTX, Paclitaxel; PEG-PMs, PEG-PLA/PTX Polymer Micelles; TfR-T12-PMs,TfR-T12-PEG-PLA/PTX Polymer Micelles.




Figure S7: Fluorescence distribution of brain tissue in health mice, DiR was loaded in PEG-PMs and TfR-T12-PMs in this study, data are depicted as means \pm SD, n = 3, *P < 0.05.

Abbreviations: PEG-PMs, PEG-PLA/PTX Polymer Micelles; TfR-T12-PMs, TfR-T12-PEG-PLA/PTX Polymer Micelles.




Figure S8: Fluorescence distribution of heart, liver, spleen, lung, kidney and tumor in subcutaneous tumor model, n = 3.

Abbreviations: PEG-PMs, PEG-PLA/PTX Polymer Micelles; TfR-T12-PMs, TfR-T12-PEG-PLA/PTX Polymer Micelles.




Figure S9: H&E stained for heart, liver, spleen, lung and kidney sections of U87MG subcutaneous bearing mice treated with saline, PTX, PEG-PMs and TfR-T12-PMs. Health mice were taken as control; scale bar = $100\mu m$.

Abbreviations: H&E, Hematoxylin and Eosin; PTX, Paclitaxel; PEG-PMs, PEG-PLA/PTX Polymer Micelles; TfR-T12-PMs, TfR-T12-PEG-PLA/PTX Polymer Micelles.




Figure S10: Median survival of orthotopic U87MG bearing mice treated with saline, PTX, PEG-PMs and TfR-T12-PMs, n=7, *P < 0.05.

Abbreviations: PTX, Paclitaxel; PEG-PMs, PEG-PLA/PTX Polymer Micelles; TfR-

T12-PMs,TfR-T12-PEG-PLA/PTX Polymer Micelles.